Hypofractionated Radiotherapy Best in Anaplastic Thyroid Cancer
TUESDAY, May 29, 2018 -- In an orthotopic anaplastic thyroid cancer (ATC) model, hypofractionated radiotherapy (RT) is superior to conventionally fractionated RT, according to a study published online May 18 in Thyroid.
Ayman Oweida, Ph.D., from the University of Colorado Denver, and colleagues characterized the cellular response to radiation in a panel of ATC cell lines and tested alternative radiotherapy fractionation schedules.
The researchers found that the levels of CXCR4 were higher in radio-resistant than radio-sensitive cell lines. In an orthotopic ATC tumor model, hypofractionated RT resulted in significantly improved tumor growth delay, decreased regional and distant metastases, and improved overall survival compared with conventionally fractionated RT.
"Our findings demonstrate the heterogeneity of response to radiation in ATC tumors and superiority of hypofractionated RT in improving local control, metastatic spread, and survival in preclinical models," the authors write. "These data support the design of clinical trials targeting radio-resistant pathways in combination with hypofractionated RT."
© 2020 HealthDay. All rights reserved.
Posted: May 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.